India's USV Reveals Investment Plans
Manufacturing Investments And A New Formulations Unit Will Target Europe
Executive Summary
Indian firm USV plans to spend $56.4m on a new drug formulations unit in Vadodara and $11.3m to upgrade its existing API unit near Mumbai as it eyes expanded capacity and additional sales in Europe.
You may also be interested in...
USV’s Juta Gets An EU Pegfilgrastim Nod
Juta Pharma has received a positive opinion from the European Medicines Agency’s CHMP recommending granting a pan-European marketing authorization for its biosimilar pegfilgrastim, Grasustek.
USV enters Germany by snapping up Juta
Privately-owned Indian company USV is entering “the highly competitive German drug market” by acquiring local generics player Juta Pharma for an undisclosed fee. The German firm – which has “more than 50 marketing authorisations for generic drugs” – was part of Watson’s Arrow Group until a management buy-out in 2013.
USV Primes German Base With Juta Acquisition
USV is building on its play in Europe with the acquisition of Juta Pharma in Germany – a market that has been fostering generics alongside supporting innovative medicines.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: